CDX2 and myeloid leukemia: These data were confirmed in an independent myeloid leukemia model, also driven by Cdx2 (#2261) (Fig. 7h, i), suggesting that dose and scheduling may be relevant in optimizing clinical responses to Aza in MDS/AML.